TABLE 1.
In vitro activity of ceftaroline and ME1036 tested against a selected collection of 152 well-characterized CA-MRSA strains
| Antimicrobial agent | MIC (μg/ml)
|
% Of susceptible strains | % Of resistant strains | ||
|---|---|---|---|---|---|
| 50% | 90% | Range | |||
| ME1036 | 0.12 | 0.25 | 0.06-0.5 | −a | — |
| Ceftaroline | 0.5 | 0.5 | 0.25-1 | − | — |
| Ceftriaxone | 32 | >32 | 16->32 | 0.0 (0.0)b | 98.7 |
| Imipenem | ≤0.5 | ≤0.5 | ≤0.5-2 | 100.0 (0.0)b | 0.0 |
| Meropenem | 2 | 2 | ≤0.5-8 | 98.0 (0.0)b | 0.0 |
| Amoxicillin-clavulanate | 8 | >8 | 2->8 | 1.3 (0.0)b | 98.7 |
| Erythromycin | >8 | >8 | 2->8 | 1.3 | 98.0 |
| Clindamycin | ≤0.25 | ≤0.25 | ≤0.25 | 100.0 | 0.0 |
| Levofloxacin | 0.25 | 0.5 | ≤0.12->4 | 92.8 | 7.2 |
| Tetracycline | ≤0.5 | ≤0.5 | ≤0.5->16 | 94.7 | 4.6 |
| Trimethoprim-sulfamethoxazole | ≤0.25 | ≤0.25 | ≤0.25 | 100.0 | 0.0 |
| Linezolid | 2 | 2 | 1-2 | 100.0 | — |
| Daptomycin | 0.25 | 0.5 | 0.25-1 | 100.0 | 0.0 |
| Vancomycin | 1 | 1 | 0.5-2 | 100.0 | 0.0 |
a
−, no breakpoint has been established by the CLSI (2) for this category.
b
The number in parentheses indicates the percentage of strains considered to be susceptible according to CLSI M100-S17 criteria.